SynthesisJournal of epidemiology and global health2026
The Global Burden of Human Metapneumovirus in High-Risk Adults: A Systematic Literature Review and Meta-Analysis.
Synthesis in Journal of epidemiology and global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman metapneumovirus (hMPV) is an under-recognized cause of severe respiratory illness in high-risk adults. We conducted a systematic review and meta-analysis to quantify hMPV prevalence and clinical outcomes in adults with chronic underlying conditions predisposing them to severe respiratory illness, including the immunocompromised.
methodsWe searched MEDLINE, Embase, and BioRelate (January 2010 to February 2025) for studies of laboratory-confirmed hMPV in adults (≥ 18 years) with high-risk chronic or immunocompromising conditions. We extracted data on hMPV positivity and key outcomes (hospitalization, intensive care unit [ICU] admission, respiratory support, length of stay, and mortality). We performed random-effects meta-analyses for outcomes reported in ≥ 3 studies and assessed study quality using an adapted Joanna Briggs Institute checklist.
resultsWe included 72 studies. Among immunocompromised adults with hMPV infection, 55.2% (95% confidence interval [CI], 42.0-67.7%) required hospital admission. Among immunocompromised patients hospitalized with respiratory illness, hMPV was detected in 5.4% (95% CI, 2.7-10.8%). Among patients with cardiovascular disease, 11.4% (95% CI, 8.0-16.1%) tested positive for hMPV. Regarding patients with chronic respiratory conditions, 3.4% (95% CI, 2.4-5.0%) of patients with chronic obstructive pulmonary disease exacerbations and 7.6% (95% CI, 2.5-20.5%) of patients with asthma exacerbations were hMPV-positive. Among hospitalized hMPV-positive high-risk patients, 13.0% (95% CI, 8.8-18.9%) required ICU admission, 43.6% (95% CI, 34.9-52.7%) required supplemental oxygen, and 7.3% (95% CI, 1.2-33.8%) required mechanical ventilation. The mean length of hospital stay was 10.4 days (95% CI, 3.4-17.4%). The pooled case fatality ratio among hospitalized adults with hMPV infection was 2.4% (95% CI, 0.1-35.1%).
conclusionshMPV is a substantial cause of severe respiratory illness in high-risk adults. Enhanced detection, surveillance, and preventive strategies are needed to reduce hMPV-associated morbidity in vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.